Have an Implanted Defibrillator? Triple-Digit Heatwaves Could Pose Danger
By Ernie Mundell HealthDay Reporter
MONDAY, Nov. 11, 2024 -- Thousands of Americans with heart trouble have small implanted defibrillators, to help regulate their heartbeat and keep cardiac events at bay.
But new research finds that on extremely hot days, people with the devices face nearly triple the odds for a dangerous arrhythmia known as atrial fibrillation (A-fib), compared to days with cooler temperatures.
The threat is likely to rise as climate change makes triple-digit days more common, experts noted.
“Susceptible individuals living in areas at risk for markedly increased temperatures should take note of these findings and ensure that they take appropriate precautions to stay cool and hydrated,” said Dr. Sanjay Rajagopalan, an expert working with the American Heart Association (AHA). He wasn't involved in the new study.
“This may be the first study that has linked ICD detection of A-fib with temperature spikes,” Rajagopalan, a professor at Case Western Reserve University in Cleveland, said in an AHA news release. “These findings reiterate other recent research about the link between outdoor temperature and cardiovascular health. Given the rising prevalence of A-fib in the general population due to increasing age and the prevalence of obesity, we now may also have to contend with rising temperatures."
The new findings are scheduled be presented today at the AHA's annual meeting in Chicago.
The new study was led by Dr. Barrak Alahmad, a research fellow in environmental health at the Harvard T.H. Chan School of Public Health in Boston. His team tracked data on more than 2,000 patients nationwide who got either an implanted cardioverter-defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D) device between 2016 and 2023.
Patients averaged about 70 years of age and most (78%) were men. Obesity was common, and most patients had cardiomyopathies, where the heart loses its pumping efficiency.
Implanted defibrillators record episodes of A-fib, so the team correlated those episodes with the outside temperatures reported in the patient's locale on the day the A-fib occurred.
The team noted that the "optimal" outside temperature -- most likely to reduce the odds of A-fib -- is relatively cool, at between 41 and 46 degrees Fahrenheit.
However, extremely high temperature days pushed a defib user's odds for A-fib much higher.
For example, compared to the ideal outside temperature, participants had nearly three times of developing A-fib on a days registering 102.2 degrees F or higher, Alahmad's team reported.
The odds for A-fib episodes on hot days were lowest in the morning but increased through working hours, and risks rose more on workdays compared to weekends.
More research revealed that these trends were also true for long A-fib episodes -- those lasting 30 minutes or longer.
“We need to understand the physiological processes underlying these findings and concentrate on preventing conditions that trigger A-fib to minimize the burden of arrhythmias,” study co-author Dr. Theofanie Mela, a cardiac electrophysiologist at Massachusetts General Hospital in Boston, said in a AHA news release. “In the meantime, we recommend patients avoid extreme temperatures and use air conditioners so that they do not expose their bodies to the severe stress of extremely high heat.”
Because these findings were reported at a medical meeting, they should be considered preliminary until published in a peer-reviewed journal.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-11-12 06:00
Read more
- Listeria Danger Spurs Nationwide Recall of Frozen Waffles
- FDA Appoints New Head of Medical Devices
- Washington Becomes 6th State to Report Bird Flu in Humans
- Mindfulness Meditation Could Have Direct Effect in Reducing Pain
- Nipocalimab is the First and Only Investigational Therapy Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of Adults Living with Moderate-to-Severe Sjögren’s Disease
- ASN: Empagliflozin Offers Lasting Cardiorenal Benefit in CKD Patients
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions